Streetbeat News

Price Targets

RCM

Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on R1 RCM (NASDAQ:RCM) and maintained a $20 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:15 pm

CNHI

Goldman Sachs analyst Daniela Costa has maintained a Neutral rating on CNH Industrial (NYSE:CNHI) and increased the price target from $15.9 to $17.57.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:14 pm

IOT

Goldman Sachs analyst Kash Rangan has reaffirmed a Buy rating on Samsara (NYSE:IOT) and increased the price target from $31 to $35.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:11 pm

RIVN

Goldman Sachs analyst Mark Delaney has maintained a Neutral rating on Rivian Automotive (NASDAQ:RIVN) but has reduced the price target from $25 to $19.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:10 pm

FSR

Goldman Sachs analyst Mark Delaney has maintained a Sell rating on Fisker (NYSE:FSR) and reduced the price target from $2 to $1.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:08 pm

FICO

Goldman Sachs analyst George Tong has reaffirmed a Buy rating on Fair Isaac (NYSE:FICO) and increased the price target from $1156 to $1289.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:06 pm

EFX

Goldman Sachs analyst Andre Benjamin has maintained a Neutral rating on Equifax (NYSE:EFX) and increased the price target from $173 to $195.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:04 pm

ESTC

Goldman Sachs analyst Kash Rangan has maintained a Neutral rating on Elastic (NYSE:ESTC) and increased the price target from $83 to $93.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:03 pm

CRNX

Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $50 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 04, 2023 | 2:02 pm

OM

Outset Medical (NASDAQ:OM) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, 2 indifferent, and 1 somewhat bearish rating. The average 12-month price target for OM is $7.3, representing a significant decrease from the previous target of $22.20. This new target suggests a potential downside of 67.12% from the earlier projections.

Portfolio Pulse from Benzinga Insights

December 04, 2023 | 2:00 pm